Despite the progress recently, the withdrawal of the FAAH inhibitor during clinical trial and anti-obesity CB1R antagonist due adverse effects engenders cautionary approaches in clinical trials. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.